Bausch & Lomb
To see an up-to date selection of historical analyses and insights on
Bausch & Lomb,
visit our
new, dynamically updated Company Summary report pages for Bausch & Lomb.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Bausch & Lomb are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Bausch & Lomb,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| Bausch & Lomb |
1 |
Ocuvite/PreserVision AREDS |
retinol, ascorbic acid & tocopherol |
Vitamin A, C & E |
134 |
143 |
|
7% |
|
|
|
2 |
Lotemax |
loteprednol etabonate |
Corticosteroid |
31 |
35 |
|
15% |
|
|
|
3 |
Retisert |
fluocinolone |
Corticosteroid |
16 |
23 |
|
41% |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
|
|
Rank |
Product |
Therapeutic Category |
Therapeutic Subcategory |
Pharmacological Class |
Phase (Current) |
| Bausch & Lomb |
- |
BOL-303224-A (SS-734) |
Sensory Organs |
Eye preparations |
Quinolone |
Filed |
|
|
- |
rPlasmin (TAL-6003) |
Sensory Organs |
Eye preparations |
Plasmin |
Phase I |
|
|
- |
Opthalmic Angiogenesis Inhibitors (PTC Therapeutics) |
Sensory Organs |
Eye preparations |
Angiogenesis inhibitor |
Pre-clinical |
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Bausch & Lomb |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
|
|
| Valuing the Enterprise |
| Free Cash Flow (Pre-Dividends) |
158 |
65 |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
2,354 |
2,292 |
| Cost of Goods Sold |
(983) |
(1,005) |
| S,G & A |
(910) |
(977) |
| R&D |
(178) |
(197) |
| Other Income/ Expense - Net |
0 |
0 |
| EBIT - Normalised |
284 |
114 |
| Net Interest & Financial Items |
(37) |
(47) |
| Pre-tax Profits - Normalised |
246 |
68 |
| Income Before Taxes |
246 |
68 |
| Tax |
(221) |
(54) |
| Tax Rate (%) |
89.9% |
79.7% |
| Minorities |
(6) |
1 |
| Net Income - Reported |
19 |
15 |
| Net Income - Normalised |
19 |
15 |
|
|
| Per Share Data |
| EPS - Diluted |
0.34 |
0.27 |
| EPS - Basic |
0.36 |
0.28 |
| EPS - Normalised (diluted) |
0.34 |
0.27 |
| EPS - Normalised (basic) |
0.36 |
0.28 |
| Avg. Shares Outstanding - Diluted |
55.7 |
55.1 |
| Avg. Shares Outstanding - Basic |
53.1 |
53.8 |
| DPS |
0.52 |
0.52 |
|
|
|
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop
|
(Bausch & Lomb)
|
05-Dec-2008 |
| FDA Approves Bausch & Lomb Akreos™ Advanced Optics Aspheric Lens
|
(Bausch & Lomb)
|
15-Sep-2008 |
| Bausch & Lomb Introduces the Crystalens® HD Accommodating Intraocular Lens to European at ESCRS 2008
|
(Bausch & Lomb)
|
12-Sep-2008 |
| Bausch & Lomb Announces European Launch of Innovative Zyoptix® Advanced Control Eyetracking (ACE™) Technology at the ESCRS 2008
|
(Bausch & Lomb)
|
12-Sep-2008 |
| Crystalens HD™ Receives FDA Approval
|
(Bausch & Lomb)
|
30-Jun-2008 |
| Bausch & Lomb Announces Positive Clinical Results for Zylet® in a Comparison of Safety and Efficacy with Tobradex in the Treatment of Blepharokerato Conjunctivitis
|
(Bausch & Lomb)
|
20-Feb-2008 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Bausch & Lomb |
Alaway |
ketotifen fumarate |
|
|
Alrex |
loteprednol etabonate |
|
|
Amvisc |
sodium hyaluronate |
|
|
Amvisc Plus |
hyaluronic acid |
|
|
Bacitracin & Polymyxin |
bacitracin & polymyxin |
|
|
BOL-303224-A (SS-734) |
besifloxacin |
|
|
Brimonidine |
brimonidine tartrate |
|
|
Carteol |
carteolol |
|
|
Ciprofloxacin |
ciprofloxacin |
|
|
Crolom |
cromolyn sodium |
|
|
Desmopressin acetate |
desmopressin acetate |
|
|
Desomedine |
hexamidine |
|
|
Diclofenamide |
diclofenamide |
|
|
Gentamicin |
gentamicin |
|
|
Indocollyre |
indomethacin |
|
|
Inflammatory ophthalmic diseases Research project |
- |
|
|
Levobunolol |
levobunolol |
|
|
Lotemax |
loteprednol etabonate |
|
|
Minims |
- |
|
|
Muro-128 |
sodium chloride |
|
|
Neomycin, Polymyxin & Gramicidin |
neomycin, polymyxin & gramicidin |
|
|
Neomycin, Polymyxin & Hydrocortisone |
neomycin, polymyxin & hydrocortisone |
|
|
Ocucoat |
hydroxypropyl methylcellulose |
|
|
Ocuvite/PreserVision AREDS |
retinol, ascorbic acid & tocopherol |
|
|
Ofloxacin |
ofloxacin |
|
|
Opcon-A |
naphazoline hydrochloride & pheniramine maleate |
|
|
Ophthalmic Disease Research Project |
- |
|
|
Opthalmic Angiogenesis Inhibitors (Cephalon) |
- |
|
|
Opthalmic Angiogenesis Inhibitors (PTC Therapeutics) |
- |
|
|
Optipranolol |
metipranolol |
|
|
Optivar |
azelastine |
|
|
Prednisolone Sodium Phosphate |
prednisolone sodium phosphate |
|
|
Retisert |
fluocinolone |
|
|
rPlasmin (TAL-6003) |
plasmin |
|
|
Selective Glucocorticoid Receptor Agonists (SEGRAs) |
- |
|
|
Sulfacetamide Sodium & Prednisolone |
prednisolone acetate & sulfacetamide sodium |
|
|
Timolol maleate |
timolol maleate |
|
|
Tobramycin |
tobramycin |
|
|
Tobramycin & Dexamethasone |
tobramycin & dexamethasone |
|
|
Trimethoprim & Polymyxin |
trimethoprim & polymyxin |
|
|
Vidisic |
cetrimide & polyacrylic acid |
|
|
Vistide |
cidofovir |
|
|
Vitrasert |
ganciclovir |
|
|
Zylet |
loteprednol etabonate & tobramycin |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
